乳腺癌患者血清血管内皮生长因子水平与临床病理特征及新辅助化疗疗效的相关性  

Relationship between levels of serum VEGF in different molecular subtypes of breast cancer and response to neoadjuvant chemotherapy

作　　者：邓伟雄[1] 汤勇才[1] 张年伟[1] 常颖智[1] 罗时敏[1] 谭卫民[1] 

机构地区：[1]广州市第一人民医院综合外科,510180

出　　处：《实用医学杂志》2015年第18期2963-2965,共3页The Journal of Practical Medicine

基　　金：国家临床重点专科建设项目经费资助

摘　　要：目的:检测不同分子病理特征的乳腺癌患者血清血管内皮生长因子(VEGF)水平,探讨其与新辅助化疗疗效的相关性。方法:通过ELISA方法对75例实施新辅助化疗的患者分别于化疗前、化疗3周期后检测血清VEGF水平,同时通过临床测量、超声检查、核磁共振等方法评估化疗疗效。结果:在腋窝淋巴结转移≥4个的乳腺癌患者中,血清VEGF水平明显高于淋巴结转移<4个的乳腺癌患者[(307.31±101.42)pg/m L vs.(170.16±73.07)pg/m L,P=0.017];在HER-2(+)乳腺癌中,血清VEGF水平较HER-2(-)患者显著增高[(235.15±88.42)pg/m L vs.(179.82±69.90)pg/m L,P=0.024];不同病理类型、绝经前后及不同激素受体表达状态患者间血清VEGF水平未见明显差异。在新辅助化疗c CR及c PR的患者中,化疗前血清VEGF水平分别为(205.75±78.12)pg/m L和(226.04±89.04)pg/m L,化疗3周期后为(145.15±67.08)pg/m L及(161.27±93.57)pg/m L,两者差异显著(P=0.009,0.014),而在疗效评估为无效(SD+PD)的患者中,化疗前后血清VEGF水平未见明显变化(P=0.577)。结论:血清VEGF水平与乳腺癌的淋巴结转移及HER-2基因表达具有相关性,新辅助化疗可降低乳腺癌患者血清VEGF的水平,能否作为新辅助化疗的疗效判定指标有待进一步研究。Objective To observe the levels of serum VEGF in different molecular subtypes of breast cancer and explore its relationship with response to neoadjuvant chemotherapy. Methods Levels of serum VEGF in 110 cases with breast cancer underwent neoadjuvant chemotherapy were detected by ELISA prior to and after3 cycles of neoadjuvant chemotherapy. Clinical response to neoadjuvant chemotherapy was evaluated by physical examination and ultrasonography. Results Levels of serum VEGF were significantly increased in breast cancer patients with≥4 lymph node metastasis than those with 4 lymph node [（307.31 ± 101.42） pg / m L vs.（170.16± 73.07） pg / m L,P = 0.017]. Patients with positive HER-2 status had significantly higher levels of serum VEGF than those with HER-2 negative status [（235.15 ± 88.42） pg / m L vs.（179.82 ± 69.90） pg / m L, P = 0.024].No significant difference was observed among age, menopausal status and hormone status. In patients with neoadjuvant chemotherapy of c CR and Cpr,the mean levels of serum VEGF were（205.75 ± 78.12） pg / m L and（226.04 ± 89.04） pg / m L, respectively. After 3 cycles of chemotherapy, levels of serum VEGF decreased to（145.15 ± 67.08） pg / m L and（161.27 ± 93.57） pg / m L. There was significant difference between two groups（P=0.009,0.014）. In patients with SD or PD response, no significant difference was observed between levels of serum VEGF before and after chemotherapy（P = 0.577）. Conclusions Levels of serum VEGF in breast cancer correlate with lymph nodes metastasis and HER-2 status and may decrease after neoadjuvant chemotherapy.However,whether or not the levels of serum VEGF can be used as a biomarker for response to neoadjuvant chemotherapy needs more further studies.

关 键 词：乳腺肿瘤 血管内皮生长因子 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]